1. Home
  2. THH vs BTAI Comparison

THH vs BTAI Comparison

Compare THH & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

THH

TryHard Holdings Limited Ordinary Shares

N/A

Current Price

$0.61

Market Cap

48.0M

Sector

N/A

ML Signal

N/A

Logo BioXcel Therapeutics Inc.

BTAI

BioXcel Therapeutics Inc.

HOLD

Current Price

$1.50

Market Cap

43.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
THH
BTAI
Founded
2013
2017
Country
Japan
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
48.0M
43.7M
IPO Year
2025
2018

Fundamental Metrics

Financial Performance
Metric
THH
BTAI
Price
$0.61
$1.50
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$26.67
AVG Volume (30 Days)
9.4M
639.5K
Earning Date
02-18-2026
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.00
N/A
Revenue
$24,528,835.00
$752,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$265.60
P/E Ratio
$319.81
N/A
Revenue Growth
2.24
N/A
52 Week Low
$0.50
$1.17
52 Week High
$55.05
$8.08

Technical Indicators

Market Signals
Indicator
THH
BTAI
Relative Strength Index (RSI) 40.41 31.36
Support Level $0.67 $1.52
Resistance Level $1.46 $1.63
Average True Range (ATR) 2.25 0.12
MACD -0.77 -0.03
Stochastic Oscillator 0.36 7.75

Price Performance

Historical Comparison
THH
BTAI

About THH TryHard Holdings Limited Ordinary Shares

Tryhard Holdings Ltd is a Japan-based lifestyle entertainment company offering services across the entertainment and hospitality sectors. Its main businesses include event curation, consultancy and management, sub-leasing of venues, and restaurant operations. The company operates through four segments, with the majority of revenue generated from consultancy and management, which provides club planning, operations, event production, entertainer bookings, and sponsorship services. The event curation segment produces both in-house and client events; the sub-leasing segment rents venues and sub-leases them to clubs; and the restaurants segment operates themed dining outlets that complement its entertainment offerings.

About BTAI BioXcel Therapeutics Inc.

BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

Share on Social Networks: